Exscientia Company
Founded in 2012 in Oxford, UK, Exscientia is a pioneer in AI-driven precision drug design. The company develops small-molecule drugs designed by its AI platform, advancing candidates in oncology, immunology, and inflammation. Exscientia partners with pharma and maintains internal programs, with several AI-designed molecules reaching clinical trials. It became one of the first AI drug-discovery companies to IPO (NASDAQ, 2021). (exscientia.ai)
Investors
%20.jpg)
Connections from
Headquarters:
Oxford Science Park, The Schrödinger Building, Oxford OX4 4GE, United Kingdom
Founded Date:
2012
Estimated Revenue:
€30.03M (FY2024)